Quantcast
Last updated on April 18, 2014 at 9:36 EDT

Latest carfilzomib Stories

2014-04-07 08:29:25

CALGARY, April 7, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that research collaborators will make two poster presentations at the American Association for Cancer Research 2014 Annual Meeting. The Meeting is being held from April 6(th) to 9(th), 2014 in San Diego, CA. "The data presented by these collaborators is contributing to our evolving understanding of how REOLSYIN(®) works, what biomarkers may be predictive of improved...

2014-03-27 08:35:29

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/48gc9x/therapeutic_class ) has announced the addition of the "Therapeutic Class Overview: Treating Refractory Hematological Malignancies" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable...

2014-02-04 08:34:36

Robust Clinical Data on Filanesib Presented at ASH Supporting Announced Registration Program BOULDER, Colo., Feb. 4, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the second quarter of its fiscal year ending June 30, 2014. (Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Revenue for the second quarter of fiscal 2014 was $14.1 million, compared to $18.4 million for the same period last year. The decrease was due to license...

2013-12-09 08:29:18

Filanesib demonstrated clinical activity as a single agent and in combination with proteasome inhibitors BOULDER, Colo., Dec. 9, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) announced positive data for newly named filanesib (ARRY-520) as a single agent and in combination with proteasome inhibitors (PI) in patients with multiple myeloma (MM) at the 2013 Annual Meeting of the American Society of Hematology. (Logo:...

2013-12-06 23:23:51

“Dual Inhibition Of Mcl-1 By The Combination Of Carfilzomib and TG02 In Multiple Myeloma” and “Leukemia Stem/Progenitor Cells From AML Patients Treated With The Multi-Kinase Inhibitor TG02 Demonstrate Increased Proliferation and Are Sensitized To Chemotherapeutic Agents” San Diego (PRWEB) December 06, 2013 Tragara Pharmaceuticals, Inc. today announced that two posters on TG02, the Company's unique oral multi-kinase inhibitor, will be presented at the American Society of...

2013-12-03 23:27:34

TG02 synergizes with carfilzomib in multiple myeloma models; data to be presented at ASH 2013 Annual Meeting. San Diego (PRWEB) December 03, 2013 Tragara Pharmaceuticals, Inc. today announced the initiation of a phase 1b clinical trial of TG02, in combination with the poteosome inhibitor carfilzomib (Kyprolis®), in patients with relapsed or refractory multiple myeloma. TG02 is a potent oral inhibitor of CDK9, which leads to the depletion of key survival proteins, such as Mcl-1,...

2013-11-11 20:21:37

BOULDER, Colo., Nov. 11, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the following upcoming conferences. The public is welcome to participate in the conferences through webcasts on the Array BioPharma website: www.arraybiopharma.com. (Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Event: Jefferies 2013 Global Healthcare...

2013-11-07 16:32:23

THOUSAND OAKS and SOUTH SAN FRANCISCO, Calif., Nov. 7, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that nearly 40 company-sponsored and investigator-sponsored investigational studies evaluating carfilzomib, a second-generation proteasome inhibitor, and oprozomib, an oral second-generation proteasome inhibitor in early development, will be presented at the 55(th) American Society of Hematology (ASH) Annual Meeting and Exposition on...

2013-11-07 08:33:50

BOULDER, Colo., Nov. 7, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that five abstracts were accepted for presentation, including two oral presentations, at the 2013 Annual Meeting of the American Society of Hematology (ASH) on its two wholly-owned hematology drug candidates, ARRY-520, a KSP inhibitor, and ARRY-614, a dual p38/Tie2 inhibitor. (Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Ron Squarer, Chief Executive Officer of Array,...

2013-10-31 08:32:38

ARRY-520 Multiple Myeloma Registration Study Expected in 2014 BOULDER, Colo., Oct. 31, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the first quarter of its fiscal year ending June 30, 2014. (Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Revenue for the first quarter of fiscal 2014 was $14.2 million, compared to $15.8 million for the same period in fiscal 2013. The cost of partnered programs increased to $10.7 million,...